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β-Catenin is a major transducer of the Wnt signaling pathway, which is aberrantly expressed in colorectal and
other cancers. Previously, we showed that β-catenin is downregulated by the 90K glycoprotein via ISGylation-
dependent degradation. However, the further mechanisms of β-catenin degradation by 90K-mediated ISGylation
pathway were not investigated. This study aimed to identify the β-catenin domain responsible for the action of
90K and to compare the mechanism of 90K on β-catenin degradation with phosphorylation-dependent
ubiquitinational degradation of β-catenin. The deletion mutants of β-catenin lacking N- or C-terminal domain or
mutating the N-terminal lysine or nonlysine residue were employed to delineate the characteristics of β-catenin
degradation by 90K-mediated ISGylation pathway. 90K induced Herc5 and ISG15 expression and reduced β-
catenin levels in HeLa and CSC221 cells. The N-terminus of β-catenin is required for 90K-induced β-catenin
degradation, but the N-terminus of β-catenin is not essential for interaction with Herc5. However, substituting
lysine residues in the N-terminus of β-catenin with arginine or deleting serine or threonine residue containing
domains from the N-terminus does not affect 90K-induced β-catenin degradation, indicating that the N-terminal 86
amino acids of β-catenin are crucial for 90K-mediated ISGylation/degradation of β-catenin in which the responsible
lysine or nonlysine residues were not identified. Our present results highlight the action of 90K on promoting
degradation of mutant β-catenin lacking the phosphorylation sites in the N-terminus. It provides further insights
into the discrete pathway downregulating the stabilized β-catenin via acquiring mutations at the serine/threonine
residues in the N-terminus.
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90K is a glycoprotein present at increased concentrations in the serum
of individuals with various cancers or viral infections. It was originally
identified as a tumor-associated antigen released into the culture
medium by human breast cancer cells and was named 90K after its
molecular mass. 90K has an N-glycosylated N-terminal signal
peptide, meaning that it is secreted into the extracellular matrix via
the secretory pathway [1]. The glycoprotein is also implicated in
immune defense and immune regulation. 90K is present in human
serum, biological fluids, and epithelial tissues; in addition, tumor cells
within human neoplastic tissues show strong upregulation of 90K,
whereas normal tissues show weak or no expression [2]. In breast
cancer patients, a high level of 90K (N11 μg/ml of serum) is a poor
prognostic factor [3], whereas high expression on immunohisto-
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prognosis for both disease-free and overall survival [2]. 90K is also
overexpressed in prostate cancer [4] and colorectal cancer (CRC)
compared with normal tissues [5]. By contrast, 90K also has positive
effects. For example, tumor cells engineered to overexpress 90K show
reduced tumorigenic potential in nude mice [6] and syngeneic mice
[7]; however, the lack of 90K expression in laryngeal cancer is
associated with the presence of known markers of aggressiveness and
shorter survival [1].
β-Catenin, a component of the cadherin-catenin complex, is a
major effector/transcription factor of the canonical Wnt signaling
pathway. Wnt binds the Frizzeled receptor and phosphorylates
Disheveled (Dvl) and other adenomatous polyposis coli (APC)
complexes, leading to the accumulation of β-catenin [8]. Accumu-
lated β-catenin associates with members of the lymphoid
enhancer-binding factor/T-cell factor (LEF/TCF) family to regulate
specific target genes such as c-myc, cyclin D1, CD44, and Axin2 [9].
Over 90% of CRC patients harbor mutations in APC or β-catenin,
leading to β-catenin accumulation in the nucleus; thus, β-catenin
plays an important role during progression of CRC [10,11]. In
normal cells, β-catenin is degraded by two APC-dependent
proteasomal degradation pathways, one involving GSK3β and the
other involving p53-Siah-1 [12,13].
Previously, we showed that β-catenin undergoes 90K-mediated
degradation via an ISG15-dependent proteasomal degradation
pathway [7] and that proteasomal degradation of β-catenin by 90K
does not require APC and is independent of GSK3β and Siah; these
findings suggest the presence of another ubiquitination pathway for
90K-mediated β-catenin degradation. Here, we used deletion
mutants lacking the N- or C-terminal domains of β-catenin or
mutating the N-terminal lysine or nonlysine residue to characterize
the β-catenin degradation by 90K-mediated ISGylation pathway. We
also asked whether the mechanism of 90K on β-catenin degradation
has any advantage on the regulation of β-catenin expression compared
with phosphorylation-dependent degradation of β-catenin by Axin/
APC/GSK3β complex, a central part of Wnt/β-catenin pathway. We
found that removing all lysine, serine, and threonine
residue-containing domains from the N-terminus of β-catenin does
not affect 90K-induced β-catenin degradation. It indicated that 90K
glycoprotein promotes degradation of mutant β-catenin lacking the
ISGylation or phosphorylation sites in the N-terminus, which
acquires stability from phosphorylation-dependent degradation and
is very commonly found in CRC tissues. This action of 90K on
β-catenin degradation has advantage on the regulation of β-catenin
expression compared with phosphorylation-dependent degradation of




The construction of full-length, ΔN, ΔC, and ARM β-catenin
tagged with green fluorescent protein (GFP) has been described
previously [14]. All other β-catenin constructs were generated using a
polymerase chain reaction–based EZchange site-directed mutagenesis
kit (Enzynomics, Daejeon, Korea). All constructs were confirmed by
sequencing. The ISG15 E1 and E2 enzyme, Ube1L and UbcH8,
respectively, expression plasmids were kindly provided by Prof. Keun
Il Kim (Sookmyung Women's University, Seoul, Korea).The following antibodies were used in the present study:
anti–β-catenin (#9582; Cell Signaling Technology), anti-Herc5
(H00051191-A01; Abnova), anti-ISG15 (sc-69,701; Santa Cruz
Biotechnology), anti-actin (A2066; Sigma), anti-myc (M047–3;
MBL), and anti-GFP (sc-8344; Santa Cruz Biotechnology).
Cell Culture, Transfection, and Reagents
HEK293T (human embryonic kidney) and HeLa (human cervical
cancer) cell lines were purchased from the Korean Cell Line Bank
(Seoul, South Korea), and CSC221 (human colorectal
adenocarcinoma–enriched cancer stem cell) cell line was purchased
from the BioMedicure (San Diego, CA). HEK293T and HeLa cells
used in the study were authenticated by a commercial service (Korean
Cell Line Bank) with short tandem repeat profiling. HEK293T,
HeLa, and CSC221 cells were maintained in RPMI or DMEM,
supplemented with 10% FBS and 1% penicillin/streptomycin at
37°C in a 5% CO2 atmosphere. HEK293T cells stably expressing a
90K-myc were generated as previously described [7]. Transfection
of siRNAs was performed using Lipofectamine RNAiMAX
(Invitrogen), according to the manufacturer's instructions. The
sequence of the 90K siRNA was 5′-ACAAATGTCTATCAACTT-
TAA-3′. Herc5 siRNA was purchased from the Thermo Fisher
Scientific (Waltham, MA).
Preparation of 90K-Conditioned Medium
90K-conditioned medium (90K/CM) was prepared as previously
described [7]. Briefly, HEK293T cells were stably transfected with a
90K-myc expression plasmid and incubated in serum-free culture
medium. After 4 days, the medium was collected and filtered to
remove cells and debris. Control conditioned medium was obtained
from HEK293T cells transfected with a mock vector. The
concentration of 90K in 90K/CM (521.5 ng/ml) was determined
by enzyme-linked immunosorbent assay [7]. The verified conditioned
media were then used to treat cells (volume used = 10% of the volume
of the culture medium).
Immunoblotting and Immunoprecipitation
Immunoprecipitation and immunoblotting were performed as
previously described [15]. Briefly, cells were harvested after washing
with ice-cold phosphate buffered saline and lysed in an ice-cold lysis
buffer. Immunoprecipitation was performed by incubating cell lysates
with an appropriate primary antibody for 16 hours at 4°C.
Immunoprecipitated complexes were then pulled down using protein
G-Sepharose beads (GE Healthcare). Cell lysates or immunopreci-
pitated proteins were resolved by electrophoresis and transferred to
PVDF membranes. Proteins were visualized using appropriated
primary antibody followed by horseradish peroxidase–conjugated
secondary antibody. Blots were developed with the enhanced
chemiluminescence solution. Images were obtained and analyzed by
a LAS4000 luminescent image analyzer (Fuji Photo Film). All results
are representative of at least three independent experiments.
The study protocol was reviewed and approved by the Institutional
Review Board of Chonnam National University Medical School
Research Institution (2013-19).
Statistical Analysis
Experimental differences were tested for statistical significance by
using analysis of variance followed by Tukey honestly significant
difference post hoc test or Student's t test. All statistical tests were
620 90K Glycoprotein in Mutant β-Catenin Park et al. Neoplasia Vol. 18, No. 10, 2016two-sided, and P values of less than .05 were considered statistically
significant. Statistical analysis was performed with PASW Statistics 20
(SPSS, an IBM Company, Chicago, IL) software.
Results
N-Terminus of β-Catenin for 90K-Induced
β-Catenin Degradation
We previously reported that glycoprotein 90K suppresses the Wnt/
β-catenin signal in colorectal cancer tissues by promoting ISGylational
(ISG15-conjugation) degradation of β-catenin [7]. 90K treatment
increases expression of ISG15 mRNA in 293T, HCT116, and Caco2
cells and promotes association of the HECT E3 ligase, Herc5, with
β-catenin. Here, we examined the effects of 90K on HeLa (cervical
cancer) and CSC221 (colorectal adenocarcinoma–enriched cancer stem
cell) cells. As shown in Figure 1A, 90K/CM treatment significantly
induced Herc5 and ISG15 expression and significantly reduced
β-catenin levels in both cell lines, indicating that 90K treatment can
promote ISGylational degradation of β-catenin in cervical cancer cells
and CRC cells–enriched cancer stem cell, in addition to CRC cells.
Next, we used several β-catenin deletion mutants to identify the
β-catenin domain responsible for 90K-induced degradation. The N-
and C-terminal domains of β-catenin are sensitive to mild protease
digestion, and both play a role inmediating protein-protein interactions
[16]. Also, the central structural core comprising 12 armadillo repeats
forms the binding surface for β-catenin ligands [16]. Therefore, three
mutants were constructed: ΔN86 (lacking the N-terminal 1-86 aa),ΔC
(lacking the C-terminal 659-781 aa), and ARM (lacking both the N-
and C-termini) [14]. We found it interesting that deleting the
N-terminal 86 aa of β-catenin completely abolished the ability of 90K to
degrade β-catenin (Figure 1B). We transfected cells stably overexpress-
ing 90K with si-90K and used them to examine the effect of 90K/CM
on the β-catenin deletion mutants. β-Catenin deletion mutants lacking
the N-terminus showed no response to 90K silencing (Figure 1C). This
clearly suggests that the N-terminal 86 aa of β-catenin are required for
90K-induced β-catenin degradation.
N-Terminus of β-Catenin for Herc5 Interaction
Because deletion of the N-terminal 86 aa of β-catenin completely
abolished the effect of 90K, the N-terminus may either contain
residue(s) required for ISG15-conjugation or play a crucial role in the
association with ISG15 E3 ligase. As shown in Figure 2A, Herc5 is
essential for 90K-induced β-catenin degradation. To determine
whether the N-terminus of β-catenin is required for the interaction
with Herc5 (the E3 ligase required for ISG15-conjugation to
β-catenin), we performed an immunoprecipitation assay to measure
the interaction between Herc5 and full-length (FL) or ΔN86 mutants
of β-catenin. To rule out the involvement of unexpected possibility in
mediating Herc5 interaction, ISG15 E1 and E2 enzyme, Ube1L and
UbcH8, respectively, were overexpressed. We observed a clear
interaction between Herc5 and ΔN86-β-catenin (Figure 2). These
results suggest that the N-terminal 86 aa of β-catenin are not essential
for its interaction with the E3 ligase, Herc5.
N-Terminal Mutation or Deletion of β-Catenin for 90K-
Induced β-Catenin Degradation
Because Herc5 interacts with both FL- and ΔN86-β-catenin,
N-terminal β-catenin likely harbors residues directly involved in the
conjugation of ISG15. Therefore, to identify the residue(s) in theN-terminus of β-catenin that is(are) responsible for ISG15 conjugation,
we compared the N-terminal aa sequence of β-catenin with the
sequences published in previous studies reporting the consensus motif
required for conjugation of ISG15. ISG15 conjugation occurs on the
ε-amine group of lysine residues [17] or on cysteine residues [18]. As
shown in Figure 3A, we identified two lysine residues (Lys-19 and
Lys-49); however, the 86 aa N-terminus of β-catenin contains no
cysteine residues. Although not reported for ISG15 conjugation,
noncanonical residues such as serine or threonine are modified by
ubiquitin even though lysine residues are the favored target for ubiquitin
conjugation [19]. We identified nine serine residues (Ser-23, Ser-29,
Ser-33, Ser-37, Ser-45, Ser-47, Ser-60, Ser-71, and Ser-73) and six
threonine residues (Thr-3, Thr-40, Thr-41, Thr-42, Thr-59, and
Thr-75) within the 86 aa N-terminus of β-catenin (Figure 3A).
To examine whether the N-terminal lysine residues of β-catenin
are responsible for 90K-induced β-catenin degradation, we substitut-
ed Lys-19 and/or Lys-49 with arginine. Surprisingly, the introduction
of single or double substitutions did not abrogate the ability of 90K to
degrade β-catenin, suggesting that the lysine residues within the
N-terminus of β-catenin are not the sole target for ISG15-
conjugation (Figure 3B).
Next, to examine whether the nonlysine residues within the
N-terminus of β-catenin are responsible for 90K-induced β-catenin
degradation, deletion mutations were introduced into the domain
containing serine or threonine residues. Three mutants harboring
specific deletions at sites between Lys-19 and Lys-49 [Δ19-31
(deletion includes Lys-19, Ser-23, and Ser-29), Δ32-39 (deletion
includes Ser-33 and Ser-37), and Δ40-48 (deletion includes Thr-40,
Thr-41, Thr-42, Ser-45, and Ser-47)] were generated. As shown in
Figure 3C, deletion of the abovementioned serine or threonine
residues had no effect on 90K-induced β-catenin degradation.
Mutants Δ59-60 (including Thr-59 and Ser-60) and Δ71-75
(including Ser-71, Ser-73, and Thr-75) harbored specific deletions
at sites beyond Lys-49 within β-catenin. Figure 3D also shows that
deletion of N-terminal β-catenin domains beyond Lys-49 did not
affect 90K-induced β-catenin degradation. Because none of the
arginine mutations or deletion mutations affected 90K-induced
β-catenin degradation, we generated two other deletion mutants
lacking either aa 1-48 (ΔN48) or aa 49-86 (ΔN49–85) of β-catenin.
Again, these deletions had no effect on 90K-induced β-catenin
degradation (Figure 3E), suggesting that 90K-induced β-catenin
degradation would still occur even if β-catenin harbored either half of
its N-terminus.
Next, we assumed that 90K-induced β-catenin degradation would
occur if there was a lysine or serine residue at the N-terminus of
β-catenin and asked whether the N-terminal 19-75 aa domain, which
contains mostly lysine, serine, and threonine residues, is required for
90K-induced β-catenin degradation. To examine this, we generated
deletion mutants lacking 19-75 aa (Δ19-75), Δ19-74 (harboring
Thr-75), and Δ20-75 (harboring Lys-19). All the deletion mutants
were degraded by 90K (Figure 4A). These mutants contained the
Thr-3 residue; therefore, we introduced the T3A mutation.
Surprisingly, all the β-catenin mutants were still degraded by 90K
(Figure 4B). Thus, even though the N-terminus of β-catenin plays an
essential role in 90K-induced β-catenin degradation, the specific
residues responsible for this activity remain unknown. At least from
Figure 4C, the results suggest that degradations of these β-catenin
mutants are dependent on Herc5 and implicate that β-catenin
N-terminus is not responsible for Herc5 interaction.
Figure 1. N-Terminus of β-catenin is required for 90K-induced β-catenin degradation. (A) 90K/CM induced Herc5 and ISG15 expression
and reduced β-catenin levels in HEK293T, HeLa, and CSC221 cells. Cells were treated with either control conditioned medium (ctrl/CM) or
90K/CM for 48 hours, followed by immunoblotting with antibodies against β-catenin, ISG15, Herc5, or actin (loading control). These
endogenous signals were measured by densitometry in triplicate experiments, and the fold changes of relative β-catenin level [A(i)], Herc5
level [A(ii)], and ISG15 [A(iii)] level compared with actin were depicted as a bar graph among three cell lines (right side). Each bar
represents mean ± SD for triplicate samples. The asterisk (*) indicates a significant difference between ctrl/CM and 90K/CM groups
(***P b .001). (B, C) Deleting the N-terminal 86 amino acids of β-catenin abolished the ability of 90K to degrade β-catenin. GFP-tagged
deletion mutants of β-catenin lacking the N-terminus (ΔN86: deletion of aa 1-86), C-terminus (ΔC: deletion of aa 659-781), or both the N-
and C-termini (ARM) were used to determine the domain responsible for 90K-induced β-catenin degradation. The exogenous β-catenin
levels (GFP-β-catenin) were measured by densitometry in triplicate experiments, and the mean fold changes of relative GFP-β-catenin
level (GFP/actin) compared with actin between ctrl/CM and 90K/CM groups were indicated below each gel lane. (B) The β-catenin deletion
mutants were transfected into HEK293T cells, which were then treated with either ctrl/CM or 90K/CM, followed by immunoblotting with
antibodies against GFP (exogenous β-catenin), endogenous β-catenin, and actin. Reductions in endogenous β-catenin levels are shown
as a positive control for the effects of 90K. The levels of FL- and ΔC-β-catenin decreased in 90K/CM-treated cells, whereas those of ΔN86-
and ARM-β-catenin remained constant. For the effect of 90K on FL-β-catenin, another enhanced image is shown as an inset. (C) The
β-catenin deletion mutants were transfected into stable 90K-myc expressing HEK293T cells together with either scrambled or
90K-specific siRNA, followed by immunoblotting with antibodies against GFP (exogenous β-catenin), myc (90K-myc), and actin. The levels
of FL- and ΔC-β-catenin increased in si-90K transfected cells. The asterisk indicates ARM β-catenin mutants, which are shown after
immunoblotting of the membrane with an anti-GFP antibody.
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Here, we examined the effects of 90K on β-catenin degradation and
tried to identify the β-catenin domain(s) responsible. The major
findings were as follows: 1) 90K induced Herc5 and ISG15
expression and reduced β-catenin levels in cervical cancer cells and
CRC cells–enriched cancer stem cell; 2) the N-terminus of β-cateninis required for 90K-induced β-catenin degradation; 3) the
N-terminus of β-catenin is not essential for interaction with Herc5;
and 4) substituting lysine residues in the N-terminus of β-catenin
with arginine or deleting serine or threonine residue-containing
domains from the N-terminus does not affect 90K-induced β-catenin
degradation.
Figure 2. β-Catenin degradation by 90K is Herc5 dependent, and ΔN86-β-catenin interacts with Herc5. (A) Herc5 silencing diminishes
90K-induced β-catenin degradation. HEK293T cells transfected with either scramble or Herc5 siRNAwere incubated for 24 hours and then
treated with ctrl/CM or 90K/CM, followed by immunoblotting with antibodies against endogenous β-catenin, Herc5, and actin. The
endogenous β-catenin levels were measured by densitometry in triplicate experiments, and the mean fold changes of relative β-catenin
level (β-ctn/actin) compared with actin between ctrl/CM and 90K/CM groups were indicated below each gel lane. (B) Both FL-β-catenin
and ΔN86-β-catenin interact with Herc5. HEK293T cells transfected with FL or ΔN86 deletion mutant of β-catenin together with Ube1L
and UbcH8 were treated with either ctrl/CM or 90K/CM, followed by immunoprecipitation with an anti-GFP antibody. Resolved bound
proteins were then immunoblotted with antibodies against Herc5 and β-catenin. Total cell lysates were immunoblotted with the
corresponding antibodies to show the input amount of each protein. The immunoprecipitated Herc5 and β-catenin levels were measured
by densitometry in triplicate experiments, and the mean fold changes (Herc5/β-ctn) between ctrl/CM and 90K/CM groups were indicated
below each gel lane.
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CK1-, and APC-mediated destruction of β-catenin [20]. Here, we
showed that the N-terminus of β-catenin is also required for
90K-induced degradation of β-catenin. Because a ΔN86 mutant of
β-catenin retained the ability to interact with Herc5, the E3 ligase
required for β-catenin ISGylation, the N-terminal 86 aa of β-catenin
should harbor ISG15-conjugation site(s), but at the same time,
mutations at the Ser/Thr residues within the N-terminal 86 aa of
β-catenin did not affect the binding of deletion mutants with Herc5
and thereby 90K could degrade these deletion mutants of β-catenin
(Figures 3 and 4). Unfortunately, we were unable to map the lysine,
serine, and/or threonine residues within the N-terminus of β-catenin
that are involved in ISG15 conjugation. The lysine residues
responsible for ISG15 conjugation have been identified in a few
proteins [17], for example, K92 of UbC13, K136 of UbCH6, K117
of EFP, K134/222 of 4EHP, K2467 of filamin B, K193/360/366 of
IRF3, K41 of the NS1 protein of influenza A virus, K139/324 of p63,
K69/159 of PKR (double-stranded RNA-activated protein kinase),
and K164/168 of PCNA. However, multiple domains appear to be
involved in ISGylation of target proteins such as HIF-1a [21] and p53
[22]. It is noteworthy that, even though K19/49 residues reside
within the N-terminal 86 aa of β-catenin, none of our single or
double arginine mutations blocked or inhibited 90K-induced
β-catenin degradation (Figure 3B).
ISG15 conjugation occurs primarily between the C-terminal
glycine of ISG15 and the ε-amino group of a lysine side chain within
the substrate protein [23]. However, conjugation of ISG15 can occur
via a disulfide bridge between the Cys87 residue of Ubc13 and the
Cys78 at the hinge region of ISG15 [18]. It is likely that canonical
ubiquitin conjugation occurs between the C-terminal Gly76 ofubiquitin and the ε-amino group of a lysine residue within the target
substrate [19]. Also, ubiquitin can be “noncanonically” conjugated to
target proteins through a thiol ester bond with the –SH group of Cys
or via an ester bond with the hydroxyl group of Ser or Thr [19].
Alternatively, ubiquitin conjugation may occur via the α-amino
group of any N-terminal residue within the target protein [24]. Of
note, “noncanonical” conjugation of ISG15 to a target protein is also
possible. Because neither single nor double arginine mutations at
K19/49 residues prevented 90K-induced β-catenin degradation, we
generated various deletion mutants of β-catenin to selectively remove
all or some of the candidate Ser or Thr residues. Unexpectedly, the
levels of all of the deletion mutants were reduced after 90K treatment
(Figure 3). The finding that the levels of ΔN86-β-catenin were not
decreased by 90K treatment ruled out the possibility of conjugation
to the α-amino group of N-terminal residues within each of the
mutants. Our present results suggest that complex regulatory
mechanisms underlie the ISGylational degradation of β-catenin by
90K, and two possibilities remain: 1) multiple residues are involved in
90K-induced conjugation of ISG15 to β-catenin, or 2) alternative
activations of lysine or nonlysine residues occur when mutations are
introduced into the N-terminus of β-catenin. Currently, either
possibility is likely to regulate β-catenin degradation.
β-Catenin mutations are commonly found in a variety of cancers, and
sequencing showed that approximately 9%of these cancer tissue samples
have somatic mutations in the N-terminal β-TrCP-binding motif of the
CTNNB1 gene [25], which results in no longer phosphorylation on
Ser33, Ser37, or Ser45 residue and not ubiquitinated and degraded and
thus, stabilized β-catenin. We previously observed that when constitu-
tively active S37A β-catenin was cotransfected with increasing doses of
90K in 293T cells, TOPFLASH activity was gradually decreased with
Figure 3. Substituting N-terminal lysine residues with arginine or deleting N-terminal serine- or threonine-containing domains from β-catenin. (A)
Schematic illustration of the β-catenin deletion mutants and the amino acid sequence of the N-terminus of β-catenin. Lysine (K, red), serine (S,
orange), and threonine (T, orange) residues within the N-terminus of β-catenin are shown in colors. Serine and threonine residues known to be
targets forGSK-3βphosphorylation are shown in blue. (B-E) Substitution ofN-terminal lysine residueswith arginine or deletingN-terminal domains
containing serine or threonine residues does not affect 90K-inducedβ-catenin degradation. Theβ-cateninmutantswere transfected intoHEK293T
cells, which were then treated with either ctrl/CM or 90K/CM, followed by immunoblotting with antibodies against GFP (exogenous β-catenin),
endogenousβ-catenin, and actin. Decreases in endogenousβ-catenin levels are shownas a positive control for the effects of 90K. Theexogenous
β-catenin levels (GFP-β-catenin) were measured by densitometry in triplicate experiments, and the fold changes of relative GFP-β-catenin level
compared with actin were depicted as a bar graph below the immunoblot data. Each bar represents mean ± SD for triplicate samples, and
number under each gel corresponds to each bar graph. The asterisk (*) indicates a significant difference between ctrl/CM and 90K/CM groups
(**P b .01; ***P b .001). (B) Introduction of arginine mutations does not affect 90K-induced β-catenin degradation. (C) Deleting serine- and
threonine-containing domains between Lys-19 and Lys-49 does not affect 90K-induced β-catenin degradation. (D) Deleting serine- and
threonine-containing domains beyond Lys-49 does not affect 90K-induced β-catenin degradation. (E) 90K-induced β-catenin degradation occurs if
β-catenin harbors either half of its N-terminal domain.
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Figure 4. Removing all lysine, serine, and threonine residue-containing domains from the N-terminus of β-catenin does not affect 90K-induced
β-catenin degradation. (A, B) The β-catenin mutants were transfected into HEK293T cells, which were then treated with either ctrl/CM or 90K/
CM, followed by immunoblotting with antibodies against GFP (exogenous β-catenin), endogenous β-catenin, and actin. Decreases in
endogenous β-catenin levels are shown as a positive control for the effects of 90K. (A) Deleting N-terminal 19-75 aa domain of β-catenin does
not affect 90K-inducedβ-catenin degradation. (B) Removing all lysine, serine, and threonine residue-containingdomains from theN-terminus of
β-catenin does not affect 90K-induced β-catenin degradation. (C) The degradations of β-catenin mutants are dependent on Herc5. HEK293T
cells transfected with either scramble or Herc5 siRNA were incubated for 24 hours and then transfected with β-catenin mutants. Then, cells
were treated with ctrl/CM or 90K/CM, followed by immunoblotting with antibodies against β-catenin, Herc5, and actin. The exogenous and
endogenous β-catenin levels were measured by densitometry in triplicate experiments, and the mean fold changes of relative β-catenin level
(exo. and endo. β-ctn/actin) compared with actin between ctrl/CM and 90K/CM groups were indicated below each gel lane.
624 90K Glycoprotein in Mutant β-Catenin Park et al. Neoplasia Vol. 18, No. 10, 2016reduced β-catenin level [7]. Our present results indicated that 90K also
promotes degradation of two β-catenin mutants harboring specific
deletions at sites Δ32-39 (deletion includes Ser-33 and Ser-37) and
Δ40-48 (deletion includes Thr-40,Thr-41, Thr-42, Ser-45, and Ser-47),
which deprive phosphorylation-dependent degradation. Thus, these
results indicated that 90K-mediated degradation of β-catenin via an
ISG15-dependent proteasomal degradation pathway could downregu-
late the stabilized β-catenin escaped from GSK3β-dependent phosphor-
ylation and provide further insights into the discrete pathwayovercoming acquired resistance to phosphorylation-dependent
β-catenin degradation via the mutations of the serine/threonine residues
in the N-terminus.
Recently, we reported that immunohistochemical expression of
90K was significantly lower in colon cancer tissues from stage IV and
its metastatic liver tissues than in that from stage I [7]. Thus,
considering these frequent loss-of-function mutations in the
N-terminal of β-catenin and suppressed 90K tissue level in advanced
colorectal cancer patients, 90K-mediated ISGylation/degradation of
Neoplasia Vol. 18, No. 10, 2016 90K Glycoprotein in Mutant β-Catenin Park et al. 625β-catenin may regulate the β-catenin level to some extent only when
the tissue level of 90K is sufficiently high to maintain ISG15
conjugation to β-catenin on multiple residues or on alternatively
activated lysine or nonlysine residues. Future studies should be
conducted to identify the further detailed mechanisms underlying
90K-mediated ISGylation of β-catenin.
In conclusion, 90K promotes degradation of mutant β-catenins
lacking the ISGylation or phosphorylation sites in the N-terminus,
which acquires stability from phosphorylation-dependent degrada-
tion. This mechanism of 90K on β-catenin degradation has advantage
on the regulation of β-catenin expression compared with
phosphorylation-dependent degradation of β-catenin by Axin/APC/
GSK3β complex, a central part of Wnt/β-catenin pathway.
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